1. <optgroup id="zyafk"></optgroup>

      <legend id="zyafk"><i id="zyafk"><del id="zyafk"></del></i></legend>

          <legend id="zyafk"></legend>

          <acronym id="zyafk"><blockquote id="zyafk"></blockquote></acronym>

        1. <acronym id="zyafk"><blockquote id="zyafk"></blockquote></acronym>
          <optgroup id="zyafk"></optgroup>

          AKS-321d and AKS-425c

          Akston is partnered with Dechra Pharmaceuticals PLC to commercialize AKS-321d and AS-425c.

          AKS-321d for dogs and AKS-425c for cats are a one-a-week insulin therapies that are a drop-in replacement to the current twice-a-day insulin treatment. They utilize a specially-designed insulin to increase glucose-lowering bioactivity and a modified dog Fc or cat Fc, which enables a long half-life through FcRn recycling, with no immune system activation. Multiple field studies have demonstrated successful multi-month treatment of dozens of client-owned diabetic dogs and cats.


          • Design balances FcRn recycling and bioactivity
          • Drop-in replacement for current therapies
          • Fc selected for species-specificity (dog and cat)
          • Fc modified to eliminate immune system activation
          • Once-a-week dosing with negligible hypoglycemia
          • Fully-biologic maufacturing

          Disease and therapy

          Approximately 80,000 dogs and 80,000 cats per year in the United States are diagnosed with diabetes, with a similar number in the European Union and an increasing number elsewhere.?Current therapy is indicated for twice-a-day subcutaneous injection and owners generally find the treatment regimen to be onerous and error-prone.? A significant number of animals are euthanized within one year of diagnosis.?Clearly, a treatment option offering satisfactory glucose control with once-a-week dosing could provide a significant improvement that owners would welcome.?

          Over 100 ultra-long acting canine and feline insulin candidates were synthesized and tested to find leads that would provide proper glucose control with weekly dosing, would not activate the animal’s immune system to produce neutralizing antibodies and could be produced efficiently at commercial scale. Akston, working with several leading academic veterinary centers including the University of California – Davis, Tufts University, and the University of Georgia, mounted studies of client-owned animals to test the final candidates. In August 2019 Akston signed a license and supply agreement for its canine insulin with Dechra Pharmaceuticals PLC.?In February 2021, Akston and Dechra Pharmaceuticals PLC signed a license and supply agreement for its feline insulin.

          Development status and plans

          Akston’s primary responsibilities in the commercialization program are manufacturing development, the preparation of CMC regulatory documentation and submissions, and the provision of AKS-321d and AKS-425c materials for pivotal safety and efficacy studies. Dechra is responsible for overseeing the pivotal safety and efficacy studies.? Dechra has successfully completed the POC study in privately-owned veterinary practices with client-owned diabetic dogs and cats.

          Akston will be the sole provider of finished drug product for sale by Dechra world-wide.? It will use its biologics manufacturing facility to produce finished AKS-321d and AKS-425c drug substance for subsequent filling and finishing.? A key impediment to the commercialization of veterinary biologics has been the high cost of candidate development and production. Akston has addressed this by employing a focused, efficient candidate selection and testing program with a production process and facility tailored to the task.